APO RESEARCH · REPORT
Human Coagulation Factor VII
Human Coagulation Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A bio similar form of recombinant activated factor VII is also available, but does not play any considerable role in the market.
Product & engineering
Understand the product.
Human Coagulation Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A bio similar form of recombinant activated factor VII is also available, but does not play any considerable role in the market.
Selected research
Market Outlook & Growth Opportunities
Global Human Coagulation Factor VII Market Outlook and Growth Opportunities 2026
Market perspective
Human Coagulation Factor VII is one of the proteins that cause blood to clot in the coagulation cascade. It is an enzyme of the serine protease class. It is sometimes used unlicensed in severe uncontrollable bleeding, although there have been safety concerns. A bio similar form of recombinant activated factor VII is also available, but does not play any considerable role in the market.
Europe and North America are the largest region of Human Coagulation Factor VII, with about 40% market share respectively. NovoNordisk is the major manufacturer of industry.
This report provides an overview of the global Human Coagulation Factor VII market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
Read the full market overview
The study covers key producers of Human Coagulation Factor VII and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Human Coagulation Factor VII sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Human Coagulation Factor VII market size, projected growth trends, production technologies, key applications, and end-use industries.
Human Coagulation Factor VII Segment by Company
NovoNordisk
Human Coagulation Factor VII Segment by Type
Recombinant Factor VIII
Plasma-derived Factor VIII
Human Coagulation Factor VII Segment by Application
Hemophilia A
Spontanous / Trauma
Surgical
Others
Human Coagulation Factor VII Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global Human Coagulation Factor VII status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Human Coagulation Factor VII market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Human Coagulation Factor VII significant trends, drivers, influence factors in global and regions.
6. To analyze Human Coagulation Factor VII competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human Coagulation Factor VII market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human Coagulation Factor VII and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human Coagulation Factor VII.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Human Coagulation Factor VII market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human Coagulation Factor VII industry.
Chapter 3: Detailed analysis of Human Coagulation Factor VII manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Human Coagulation Factor VII in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Human Coagulation Factor VII in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Factor VIII
- Plasma-derived Factor VIII
Applications
- Hemophilia A
- Spontanous / Trauma
- Surgical
- Others
Companies covered
- NovoNordisk
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.2.1 Global Human Coagulation Factor VII Sales Value (2021-2032)
- 1.2.2 Global Human Coagulation Factor VII Sales Volume (2021-2032)
- 1.2.3 Global Human Coagulation Factor VII Sales Average Price (2021-2032)
- 1.3 Assumptions and Limitations
- 1.4 Study Goals and Objectives
2 Human Coagulation Factor VII Market Dynamics
- 2.1 Human Coagulation Factor VII Industry Trends
- 2.2 Human Coagulation Factor VII Industry Drivers
- 2.3 Human Coagulation Factor VII Industry Opportunities and Challenges
- 2.4 Human Coagulation Factor VII Industry Restraints
3 Human Coagulation Factor VII Market by Company
- 3.1 Global Human Coagulation Factor VII Company Revenue Ranking in 2025
- 3.2 Global Human Coagulation Factor VII Revenue by Company (2021-2026)
- 3.3 Global Human Coagulation Factor VII Sales Volume by Company (2021-2026)
- 3.4 Global Human Coagulation Factor VII Average Price by Company (2021-2026)
- 3.5 Global Human Coagulation Factor VII Company Ranking (2024-2026)
- 3.6 Global Human Coagulation Factor VII Company Manufacturing Base and Headquarters
- 3.7 Global Human Coagulation Factor VII Company Product Type and Application
- 3.8 Global Human Coagulation Factor VII Company Establishment Date
- 3.9 Market Competitive Analysis
- 3.9.1 Global Human Coagulation Factor VII Market Concentration Ratio (CR5 and HHI)
- 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
- 3.9.3 2025 Human Coagulation Factor VII Tier 1, Tier 2, and Tier 3 Companies
- 3.10 Mergers and Acquisitions Expansion
4 Human Coagulation Factor VII Market by Type
- 4.1 Human Coagulation Factor VII Type Introduction
- 4.1.1 Recombinant Factor VIII
- 4.1.2 Plasma-derived Factor VIII
- 4.2 Global Human Coagulation Factor VII Sales Volume by Type
- 4.2.1 Global Human Coagulation Factor VII Sales Volume by Type (2021 VS 2025 VS 2032)
- 4.2.2 Global Human Coagulation Factor VII Sales Volume by Type (2021-2032)
- 4.2.3 Global Human Coagulation Factor VII Sales Volume Share by Type (2021-2032)
- 4.3 Global Human Coagulation Factor VII Sales Value by Type
- 4.3.1 Global Human Coagulation Factor VII Sales Value by Type (2021 VS 2025 VS 2032)
- 4.3.2 Global Human Coagulation Factor VII Sales Value by Type (2021-2032)
- 4.3.3 Global Human Coagulation Factor VII Sales Value Share by Type (2021-2032)
5 Human Coagulation Factor VII Market by Application
- 5.1 Human Coagulation Factor VII Application Introduction
- 5.1.1 Hemophilia A
- 5.1.2 Spontanous / Trauma
- 5.1.3 Surgical
- 5.1.4 Others
- 5.2 Global Human Coagulation Factor VII Sales Volume by Application
- 5.2.1 Global Human Coagulation Factor VII Sales Volume by Application (2021 VS 2025 VS 2032)
- 5.2.2 Global Human Coagulation Factor VII Sales Volume by Application (2021-2032)
- 5.2.3 Global Human Coagulation Factor VII Sales Volume Share by Application (2021-2032)
- 5.3 Global Human Coagulation Factor VII Sales Value by Application
- 5.3.1 Global Human Coagulation Factor VII Sales Value by Application (2021 VS 2025 VS 2032)
- 5.3.2 Global Human Coagulation Factor VII Sales Value by Application (2021-2032)
- 5.3.3 Global Human Coagulation Factor VII Sales Value Share by Application (2021-2032)
6 Human Coagulation Factor VII Regional Sales and Value Analysis
- 6.1 Global Human Coagulation Factor VII Sales by Region: 2021 VS 2025 VS 2032
- 6.2 Global Human Coagulation Factor VII Sales by Region (2021-2032)
- 6.2.1 Global Human Coagulation Factor VII Sales by Region: 2021-2026
- 6.2.2 Global Human Coagulation Factor VII Sales by Region (2027-2032)
- 6.3 Global Human Coagulation Factor VII Sales Value by Region: 2021 VS 2025 VS 2032
- 6.4 Global Human Coagulation Factor VII Sales Value by Region (2021-2032)
- 6.4.1 Global Human Coagulation Factor VII Sales Value by Region: 2021-2026
- 6.4.2 Global Human Coagulation Factor VII Sales Value by Region (2027-2032)
- 6.5 Global Human Coagulation Factor VII Market Price Analysis by Region (2021-2026)
- 6.6 North America
- 6.6.1 North America Human Coagulation Factor VII Sales Value (2021-2032)
- 6.6.2 North America Human Coagulation Factor VII Sales Value Share by Country, 2025 VS 2032
- 6.7 Europe
- 6.7.1 Europe Human Coagulation Factor VII Sales Value (2021-2032)
- 6.7.2 Europe Human Coagulation Factor VII Sales Value Share by Country, 2025 VS 2032
- 6.8 Asia-Pacific
- 6.8.1 Asia-Pacific Human Coagulation Factor VII Sales Value (2021-2032)
- 6.8.2 Asia-Pacific Human Coagulation Factor VII Sales Value Share by Country, 2025 VS 2032
- 6.9 South America
- 6.9.1 South America Human Coagulation Factor VII Sales Value (2021-2032)
- 6.9.2 South America Human Coagulation Factor VII Sales Value Share by Country, 2025 VS 2032
- 6.10 Middle East & Africa
- 6.10.1 Middle East & Africa Human Coagulation Factor VII Sales Value (2021-2032)
- 6.10.2 Middle East & Africa Human Coagulation Factor VII Sales Value Share by Country, 2025 VS 2032
7 Human Coagulation Factor VII Country-level Sales and Value Analysis
- 7.1 Global Human Coagulation Factor VII Sales by Country: 2021 VS 2025 VS 2032
- 7.2 Global Human Coagulation Factor VII Sales Value by Country: 2021 VS 2025 VS 2032
- 7.3 Global Human Coagulation Factor VII Sales by Country (2021-2032)
- 7.3.1 Global Human Coagulation Factor VII Sales by Country (2021-2026)
- 7.3.2 Global Human Coagulation Factor VII Sales by Country (2027-2032)
- 7.4 Global Human Coagulation Factor VII Sales Value by Country (2021-2032)
- 7.4.1 Global Human Coagulation Factor VII Sales Value by Country (2021-2026)
- 7.4.2 Global Human Coagulation Factor VII Sales Value by Country (2027-2032)
- 7.5 USA
- 7.5.1 USA Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.5.2 USA Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.5.3 USA Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.6 Canada
- 7.6.1 Canada Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.6.2 Canada Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Canada Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.7 Mexico
- 7.6.1 Mexico Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.6.2 Mexico Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.6.3 Mexico Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.8 Germany
- 7.8.1 Germany Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.8.2 Germany Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.8.3 Germany Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.9 France
- 7.9.1 France Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.9.2 France Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.9.3 France Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.10 U.K.
- 7.10.1 U.K. Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.10.2 U.K. Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.10.3 U.K. Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.11 Italy
- 7.11.1 Italy Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.11.2 Italy Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.11.3 Italy Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.12 Spain
- 7.12.1 Spain Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.12.2 Spain Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.12.3 Spain Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.13 Russia
- 7.13.1 Russia Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.13.2 Russia Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.13.3 Russia Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.14 Netherlands
- 7.14.1 Netherlands Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.14.2 Netherlands Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.14.3 Netherlands Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.15 Nordic Countries
- 7.15.1 Nordic Countries Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.15.2 Nordic Countries Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.15.3 Nordic Countries Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.16 China
- 7.16.1 China Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.16.2 China Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.16.3 China Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.17 Japan
- 7.17.1 Japan Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.17.2 Japan Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.17.3 Japan Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.18 South Korea
- 7.18.1 South Korea Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.18.2 South Korea Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.18.3 South Korea Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.19 India
- 7.19.1 India Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.19.2 India Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.19.3 India Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.20 Australia
- 7.20.1 Australia Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.20.2 Australia Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.20.3 Australia Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.21 Southeast Asia
- 7.21.1 Southeast Asia Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.21.2 Southeast Asia Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.21.3 Southeast Asia Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.22 Brazil
- 7.22.1 Brazil Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.22.2 Brazil Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.22.3 Brazil Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.23 Argentina
- 7.23.1 Argentina Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.23.2 Argentina Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.23.3 Argentina Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.24 Chile
- 7.24.1 Chile Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.24.2 Chile Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.24.3 Chile Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.25 Colombia
- 7.25.1 Colombia Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.25.2 Colombia Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.25.3 Colombia Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.26 Peru
- 7.26.1 Peru Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.26.2 Peru Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.26.3 Peru Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.27 Saudi Arabia
- 7.27.1 Saudi Arabia Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.27.2 Saudi Arabia Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.27.3 Saudi Arabia Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.28 Israel
- 7.28.1 Israel Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.28.2 Israel Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.28.3 Israel Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.29 UAE
- 7.29.1 UAE Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.29.2 UAE Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.29.3 UAE Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.30 Turkey
- 7.30.1 Turkey Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.30.2 Turkey Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.30.3 Turkey Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.31 Iran
- 7.31.1 Iran Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.31.2 Iran Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.31.3 Iran Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
- 7.32 Egypt
- 7.32.1 Egypt Human Coagulation Factor VII Sales Value Growth Rate (2021-2032)
- 7.32.2 Egypt Human Coagulation Factor VII Sales Value Share by Type, 2025 VS 2032
- 7.32.3 Egypt Human Coagulation Factor VII Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
- 8.1 NovoNordisk
- 8.1.1 NovoNordisk Company Information
- 8.1.2 NovoNordisk Business Overview
- 8.1.3 NovoNordisk Human Coagulation Factor VII Sales, Value and Gross Margin (2021-2026)
- 8.1.4 NovoNordisk Human Coagulation Factor VII Product Portfolio
- 8.1.5 NovoNordisk Recent Developments
9 Value Chain and Sales Channels Analysis
- 9.1 Human Coagulation Factor VII Value Chain Analysis
- 9.1.1 Human Coagulation Factor VII Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Human Coagulation Factor VII Sales Mode & Process
- 9.2 Human Coagulation Factor VII Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Human Coagulation Factor VII Distributors
- 9.2.3 Human Coagulation Factor VII Customers
10 Concluding Insights
11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst